CareDx to Participate in Upcoming Investor Conferences
06/01/2023 - 07:00 AM
BRISBANE, Calif. --(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.
CareDx’s management is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023, at 8:00 AM PT / 11:00 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com .
CareDx’s management will also be presenting at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th , 2023, at 4:40 PM PT / 7:40 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com .
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California , is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230601005225/en/
CareDx, Inc.
Media Relations
aczene@caredx.com
Investor Relations
Investor@caredx.com
Source: CareDx, Inc.
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
